Mayor, Paul

Mayo Clinic

Roswell Park Comprehensive Cancer Center

Citations 2

History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium

Minlikeeva, Albina N. , Freudenheim, Jo L. , Eng, Kevin H., Cannioto, Rikki , Friel, Grace , Szender, J. Brian, Odunsi, Kunle , Mayor, Paul , Diergaarde, Brenda , Zsíros, Emese , Kelemen, Linda E. , Köbel, Martin , Steed, Helen , DeFazio, Anna , Jordan, Susan J. , Fasching, Peter A. , Beckmann, Matthias W. , Rossing, Mary Anne, Chang‐Claude, Jenny , Goodman, Marc T. , Dörk, Thilo , Edwards, Robert P., Ness, Roberta B., Matsuo, Keitaro , Goode, Ellen L. , Høgdall, Estrid , Schildkraut, Joellen M. , Terry, Kathryn L. , Paddock, Lisa E. , Kiemeney, Lambertus A. , Massuger, Leon F.A.G. , Sutphen, Rebecca , Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Pearce, Celeste Leigh , Wu, Anna H. , Kupryjańczyk, Jolanta , Jensen, Allan , Webb, Penelope M. , Moysich, Kirsten B. , Bowtell, David D.L. , Fazio, Anna de , Dörk, Thilo , Kiemeney, Lambertus A , Ramus, Susan J , Webb, Penelope M , Köbel, Martin , Jensen, Allan , Menon, Usha , Moysich, Kirsten , Matsuo, Keitaro , Kupryjanczyk, Jolanta , Høgdall, Estrid , Bowtell, David D , Segal, Brahm H. , Risch, Harvey A. , Doherty, Jennifer A. , Modugno, Francesmary , Mizuno, Mika , Karlan, Beth Y. , Kjær, Susanne K. , Cramer, Daniel W. , Bandera, Elisa V. , Anton‐Culver, Hoda , Ziogas, Argyrios , Gentry‐Maharaj, Aleksandra , Diergaarde, Brenda , Steed, Helen , Goodman, Marc T

Cancer Epidemiology, Biomarkers & Prevention | September 1, 2017 | Volume: 26 | Issue: 9 | Pages: 1470-1473

Abstract Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients. Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes. Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced). Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival. Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470–3. ©2017 AACR.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Sucheston‐Campbell, Lara, Cannioto, Rikki , Clay‐Gilmour, Alyssa , Etter, John Lewis , Eng, Kevin H., Liu, Song , Battaglia, Sebastiano , Szender, J. Brian, Minlikeeva, Albina N. , Joseph, Janine M. , Mayor, Paul , Abrams, Scott I. , Wallace, Paul K. , Soh, Kah Teong , Zsíros, Emese , Beckmann, Matthias W. , Bruegl, Amanda , Campbell, Ian , Campbell, Shawn, Chenevix‐Trench, Georgia , Diergaarde, Brenda , Doerk, Thilo, Eccles, Diana , Engelholm, Svend Aage, Fasching, Peter A. , Gayther, Simon A. , Goodman, Marc T. , Harter, Philipp , Hein, Alexander , Heitz, Florian , Hillemmanns, Peter, Høgdall, Claus , Høgdall, Estrid , Huzarski, Tomasz , Jensen, Allan , Johnatty, Sharon E. , Jung, Audrey , Klapdor, Reudiger, Kluz, Tomasz , Konopka, Bożena , Kupryjańczyk, Jolanta , Lambrechts, Diether , Lester, Jenny, Lubiński, Jan , Levine, Douglas A. , Lundvall, Lene, McGuire, Valerie , McNeish, Iain A. , Menon, Usha , Ness, Roberta B., Oršulić, Sandra , Pearce, Celeste Leigh, Ramus, Susan J. , Rothstein, Joseph H. , Rossing, Mary Anne, Rübner, Matthias, Schildkraut, Joellen M. , Schmalfeldt, Barbara , Schwaab, Ira, Sieh, Weiva , Sobiczewski, Piotr , Song, Honglin , Terry, Kathryn L. , Nieuwenhuysen, Els Van , Vanderstichele, Adriaan , Vergote, Ignace , Walsh, Christine , Webb, Penelope M. , Wentzensen, Nicolas , Whittemore, Alice S. , Wu, Anna H. , Odunsi, Kunle , Chang‐Claude, Jenny , Goode, Ellen L. , Moysich, Kirsten B. , Dörk, Thilo , Bowtell, David D.L. , Lambrechts, Diether , Clay, Alyssa I, Hu, Qiang , Segal, Brahm H. , Anton‐Culver, Hoda , Bandera, Elisa V. , Berchuck, Andrew , Bjørge, Line , Cramer, Daniel W. , Dansonka‐Mieszkowska, Agnieszka , Dao, Fanny , Doherty, Jennifer A. , Bois, Andreas du , Gentry‐Maharaj, Aleksandra , Glasspool, Rosalind , Gronwald, Jacek , Karlan, Beth Y. , Kjær, Susanne K. , Modugno, Francesmary , Paul, James , Pejovic, Tanja B. , Pharoah, Paul D.P. , Siddiqui, Nadeem , Ziogas, Argyrios , Dörk, Thilo , Lambrechts, Diether , McNeish, Iain A , Ramus, Susan J , Vanderstichele, Adriaan , Webb, Penelope M , Hein, Alexander , Jensen, Allan , Eccles, Diana , Menon, Usha , Moysich, Kirsten , Campbell, Ian G , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Huzarski, Tomasz , Jung, Audrey Y , Bowtell, David D , Diergaarde, Brenda , Lubinski, Jan , Kluz, Tomasz , Goodman, Marc T

Cancer Epidemiology, Biomarkers & Prevention | September 28, 2016 | Volume: 26 | Issue: 3 | Pages: 420-424

10.1158/1055-9965.epi-16-0631

Abstract Background: The precise mechanism by which the immune system is adversely affected in cancer patients remains poorly understood, but the accumulation of immunosuppressive/protumorigenic myeloid-derived suppressor cells (MDSCs) is thought to be a prominent mechanism contributing to immunologic tolerance of malignant cells in epithelial ovarian cancer (EOC). To this end, we hypothesized genetic variation in MDSC pathway genes would be associated with survival after EOC diagnoses. Methods: We measured the hazard of death due to EOC within 10 years of diagnosis, overall and by invasive subtype, attributable to SNPs in 24 genes relevant in the MDSC pathway in 10,751 women diagnosed with invasive EOC. Versatile Gene-based Association Study and the admixture likelihood method were used to test gene and pathway associations with survival. Results: We did not identify individual SNPs that were significantly associated with survival after correction for multiple testing (P < 3.5 × 10−5), nor did we identify significant associations between the MDSC pathway overall, or the 24 individual genes and EOC survival. Conclusions: In this well-powered analysis, we observed no evidence that inherited variations in MDSC-associated SNPs, individual genes, or the collective genetic pathway contributed to EOC survival outcomes. Impact: Common inherited variation in genes relevant to MDSCs was not associated with survival in women diagnosed with invasive EOC. Cancer Epidemiol Biomarkers Prev; 26(3); 420–4. ©2016 AACR.